Innervace

About:

Innvervace develops regenerative therapy solutions for neurodegenerative disorders.

Top Investors: Deerfield, IP Group, BioAdvance, WARF Ventures, Penn Medicine Co-Investment Program

Description:

Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders. The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineered nigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily. Innervace was established in 2018 by in Philadelphia, Pennsylvania

Total Funding Amount:

$40M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2018-01-01

Founders:

Nader Halim

Number of Employees:

1-10

Last Funding Date:

2022-09-08

IPO Status:

Private

Industries: